Experts Forecast 2024, Part 4: Cutting-edge Tech for Oncology Drug Discovery
In part 4 of our 2024 Experts Forecast, Paul Workman, PhD, shares thoughts on cutting-edge advances in oncology drug discovery.
Progress Against Cancer
In part 4 of our 2024 Experts Forecast, Paul Workman, PhD, shares thoughts on cutting-edge advances in oncology drug discovery.
In part 3 of our 2024 Experts Forecast, AACR President-Elect Patricia M. LoRusso, DO, PhD (hc), FAACR, shares thoughts on precision medicine.
Non-invasive scanning for biomarkers after only 1 week may guide treatment for some patients with melanoma and avoid surgery in other patients. Imaging may help determine if the immunotherapeutic pembrolizumab (Keytruda) is helping patients with...
January is Cervical Cancer Awareness Month. Here's the latest on prevention, screening, and treatment.
In part 2 of our 2024 Experts Forecast, Robert A. Winn, MD, FAACR, discusses ways to achieve health equity.
What experts forecast for cancer research and treatment in 2024. Part 1: Catherine J. Wu, MD, FAACR, on cancer vaccines.
Progression-free survival among certain patients with metastatic colorectal cancer continued at a high level after immune checkpoint inhibitor therapy was stopped. Some patients with metastatic colorectal cancer who benefit from immunotherapy are reluctant to...
Ancient Greek physician Hippocrates considered the human body to be a system composed of four balanced fluids, or “humours.” The theory has long been supplanted, but contemporary oncology has brought body fluids back into...
Stool test for signs of cancer, often collected at home, sometimes fails due to inadequate sampling, according to a study in the AACR Journal Cancer Epidemiology, Biomarkers & Prevention. About a tenth of the...
As the number of targeted cancer therapeutics has increased, the percentage of tumors carrying molecular alterations eligible for treatment by those drugs nearly doubled from 2017 to 2022. Precise, biomarker-guided therapies made up almost...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More